PMID- 37258172
OWN - NLM
STAT- MEDLINE
DCOM- 20230801
LR  - 20230801
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 70
IP  - 7
DP  - 2023 Jul 28
TI  - Increased soluble endoglin levels in newly-diagnosed type 2 diabetic patients are 
      associated with endothelial dysfunction.
PG  - 711-721
LID - 10.1507/endocrj.EJ22-0550 [doi]
AB  - Endothelial dysfunction (ED) contributes to the pathologic process underlying 
      macrovascular complications, a common complication of type 2 diabetes mellitus 
      (T2DM). Soluble endoglin (sEng) shed from the extracellular domain of the entire 
      endoglin molecule blocks endothelial protection mediated by transforming growth 
      factor-beta 1 (TGF-beta1). The reactive hyperemia index (RHI), which is determined 
      by reactive hyperemia peripheral arterial tonometry (RH-PAT), is a new index with 
      which to evaluate ED. This study determined the changes in serum sEng levels in 
      newly-diagnosed (untreated) T2DM patients and the correlation with the RHI. The 
      T2DM group included 34 newly-diagnosed T2DM patients, while the control group 
      included 53 healthy adults. The clinical data from the two groups were evaluated 
      retrospectively. The intima-media thickness (IMT) of the common carotid artery 
      (CCA) and the ankle-brachial index (ABI) of both legs were used to assess 
      structural vascular changes. The serum sEng level was determined using an ELISA 
      kit. Endothelial function was assessed using RH-PAT and the RHI was computed. The 
      serum sEng level in the T2DM group was significantly greater than the control 
      group, although the RHI was significantly lower in the T2DM group (p < 0.05). The 
      serum sEng level was negatively correlated with the RHI in T2DM patents (r = 
      0.354, p = 0.041). The serum sEng level, CCA-IMT, and ABI were not significantly 
      correlated with T2DM (p > 0.05). In summary, among newly-diagnosed T2DM patients, 
      the serum sEng levels were inversely correlated with the RHI, and an elevated 
      sEng level may be associated with ED.
FAU - Dou, Xiaobing
AU  - Dou X
AD  - School of Life Science, Zhejiang Chinese Medical University, Zhejiang 310053, P. 
      R. China.
FAU - Wang, Xiujing
AU  - Wang X
AD  - Department of Endocrinology, Chinese PLA 903rd Hospital, Zhejiang 310013, P. R. 
      China.
FAU - Yu, Xiuhua
AU  - Yu X
AD  - Department of Ultrasonography, Chinese PLA 903rd Hospital, Zhejiang 310013, P. R. 
      China.
FAU - Yao, Jiaqi
AU  - Yao J
AD  - Department of Endocrinology, Chinese PLA 903rd Hospital, Zhejiang 310013, P. R. 
      China.
FAU - Shen, Huiling
AU  - Shen H
AD  - Department of Endocrinology, Chinese PLA 903rd Hospital, Zhejiang 310013, P. R. 
      China.
FAU - Xu, Yao
AU  - Xu Y
AD  - Department of Endocrinology, Chinese PLA 903rd Hospital, Zhejiang 310013, P. R. 
      China.
FAU - Zheng, Bojing
AU  - Zheng B
AD  - Department of Endocrinology, Chinese PLA 903rd Hospital, Zhejiang 310013, P. R. 
      China.
FAU - Zhang, Zhenying
AU  - Zhang Z
AD  - Department of Endocrinology, Chinese PLA 903rd Hospital, Zhejiang 310013, P. R. 
      China.
FAU - Tan, Qingying
AU  - Tan Q
AD  - Department of Endocrinology, Chinese PLA 903rd Hospital, Zhejiang 310013, P. R. 
      China.
FAU - Hu, Tianxiao
AU  - Hu T
AD  - School of Life Science, Zhejiang Chinese Medical University, Zhejiang 310053, P. 
      R. China.
AD  - Department of Endocrinology, Chinese PLA 903rd Hospital, Zhejiang 310013, P. R. 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230531
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Endoglin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis
MH  - Endoglin
MH  - *Hyperemia
MH  - Retrospective Studies
MH  - Carotid Intima-Media Thickness
MH  - Endothelium, Vascular
OTO - NOTNLM
OT  - Endothelial dysfunction
OT  - Reactive hyperemia index
OT  - Soluble endoglin
OT  - Type 2 diabetes mellitus
EDAT- 2023/06/01 01:08
MHDA- 2023/08/01 06:45
CRDT- 2023/05/31 21:38
PHST- 2023/08/01 06:45 [medline]
PHST- 2023/06/01 01:08 [pubmed]
PHST- 2023/05/31 21:38 [entrez]
AID - 10.1507/endocrj.EJ22-0550 [doi]
PST - ppublish
SO  - Endocr J. 2023 Jul 28;70(7):711-721. doi: 10.1507/endocrj.EJ22-0550. Epub 2023 
      May 31.